New hope for tough leukemias: experimental drug LBS-007 enters human testing

NCT ID NCT05756322

Recruiting now Disease control Sponsor: Lin BioScience, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called LBS-007 in adults with acute leukemias (AML or ALL) that have returned or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can control the disease. About 90 participants will receive the drug in increasing doses to check for side effects and signs of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia acute lymphoblastic leukemia acute myeloid leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR RESISTANT ACUTE LEUKAEMIAS

Contacts and locations

Locations

China Medical University Hospital
NOT_YET_RECRUITING

Taichung, Taiwan
Hollywood Private Hospital
WITHDRAWN

Nedlands, Washington, Australia
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITING

Tianjin, 300020, China
Jining No.1 People's Hospital
RECRUITING

Jining, Shandong, 272011, China
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
National Cheng Kung University Hospital
NOT_YET_RECRUITING

Tainan, Taiwan
National Taiwan University Hospital
NOT_YET_RECRUITING

Taipei, Taiwan
Pindara Private Hospital
COMPLETED

Benowa, Queensland, Australia
Q Medical Conselling
WITHDRAWN

Perth, Washington, 6009, Australia
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
NOT_YET_RECRUITING

Chicago, Illinois, 60611, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITING

Baltimore, Maryland, 21287, United States
The Alfred Hospital
ACTIVE_NOT_RECRUITING

Melbourne, Victoria, Australia
The First Affiliated Hospital of Xinxiang Medical University
RECRUITING

Xinxiang, Henan, 453100, China
The Royal Adelaide Hospital
RECRUITING

Adelaide, South Australia, Australia
The University of Kansas Hospital
RECRUITING

Fairway, Kansas, 66205, United States
UNC Hospitals, The University of North Carolina at Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27599, United States
Wollongong Private Hospital
COMPLETED

Wollongong, New South Wales, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.